Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7981041 extension study of ritlecitinib in nonsegmental vitiligo
2023-505804-42-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of ritlecitinib tosilate in nonsegmental vitiligo (3 arms), sponsored by Pfizer. Primary endpoints: Incidence of TEAEs, SAEs, and AEs leading to discontinuation and Incidence of clinically significant laboratory abnormalities. Planned start Jul 2024; status: authorised.
02
Drugs
ritlecitinib tosilate
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on 2023-505804-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505804-42-00.